Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Inclusion Criteria: * Subject is male or female, aged at least 18 years. * Subject has a histologically or cytologically confirmed diagnosis of an advanced, malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable and/or for which standard curative measures either are not applicable, or do not exist, or are no longer effective. Subjects with curative treatment options are not eligible for the protocol. * Subject is not receiving any active treatment for his/her malignancy (except for prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride). * Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at Screening. * Subject has acceptable liver function at Screening * Subject has a normal serum creatinine. * Subject has acceptable hematologic status at Screening * Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001. Exclusion Criteria: * Impaired cardiac function that in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk. * Right-to-left, bidirectional, or transient right-to-left cardiac shunts. * Subjects with a history of acute cerebral infarction or transient ischemic attack within 90 days prior to Study Day 1. * Acute myocardial infarction or acute coronary syndromes less than one year prior to enrollment. * Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the QT interval. * Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14 days prior to Study Day 1). * Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1 (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day 1). * Chemotherapy regimens given continuously or on a weekly basis that Investigator believes to have a limited potential for delayed toxicity within 14 days prior to Study Day 1. * Use of an investigational anti-cancer drug within 42 days prior to Study Day 1. * Subject has symptomatic and/or untreated central nervous system metastases and/or intracranial hypertension. * Subject has a known history of an active and/or an uncontrolled infection with hepatitis A or hepatitis B. * Subject with a known history of a positive HIV status. * Subjects with pulmonary edema. * Subjects with respiratory failure * Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature. * Subjects with Raynaud's syndrome. * Subjects with a serious co-morbid medical condition. * If female, subject is pregnant and/or breastfeeding. * Any subject with congenital or acquired methemoglobinemia. * Any subject with a history of inherited anemia or hemoglobinopathy including but not limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary ovalocytosis,